This is a preview of subscription content, log in via an institution to check access.
Reference
Meng J, et al. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. ClinicoEconomics and Outcomes Research : 23 Apr 2018. Available from: URL: https://doi.org/10.2147/CEOR.S159833
Rights and permissions
About this article
Cite this article
Cabozantinib cost effective for advanced RCC in England. PharmacoEcon Outcomes News 803, 7 (2018). https://doi.org/10.1007/s40274-018-4934-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4934-y